English
简体中文
Total: £ 56.28
Published Date: 2026-03-24 | Pages: 120 | Tables: 119 | Pharma & Healthcare
The global Gastric Mucosal Protective Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Gastric Mucosal Protective Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Gastric Mucosal Protective Drugs are a class of medications designed to protect the mucosal lining of the stomach from acidic gastric juices. They are used to treat conditions like peptic ulcers, NSAID-induced ulcers, and gastroesophageal reflux disorder (GERD). These drugs work by forming a protective barrier over the mucosa, stimulating the production of prostaglandins, mucus, and bicarbonate, which in turn helps neutralize gastric acid and promote healing.
The North American market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Gastric Mucosal Protective Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Gastric Mucosal Protective Drugs include Misoprostol (Cytotec), Sucralfate (Carafate), Bismuth Subsalicylate (Pepto-Bismol), Abbott, AstraZeneca, Cadila Healthcare, Daewoong Pharmaceutical, Eisai, Pharmaking, Taiho Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Gastric Mucosal Protective Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Gastric Mucosal Protective Drugs. The Gastric Mucosal Protective Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Gastric Mucosal Protective Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Gastric Mucosal Protective Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Misoprostol (Cytotec)
Sucralfate (Carafate)
Bismuth Subsalicylate (Pepto-Bismol)
Abbott
AstraZeneca
Cadila Healthcare
Daewoong Pharmaceutical
Eisai
Pharmaking
Taiho Pharmaceutical
Takeda Pharmaceutical
Segment by Type
Oral Medicines
Injectable Medicines
by Application
Infant patients
Child patients
Youth patients
Elderly patients
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Gastric Mucosal Protective Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Gastric Mucosal Protective Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Gastric Mucosal Protective Drugs Market Overview
1.1 Product Definition
1.2 Gastric Mucosal Protective Drugs by Type
1.2.1 Global Gastric Mucosal Protective Drugs Market Value by Type: 2025 vs 2032
1.2.2 Oral Medicines
1.2.3 Injectable Medicines
1.3 Gastric Mucosal Protective Drugs by Application
1.3.1 Global Gastric Mucosal Protective Drugs Market Value by Application: 2025 vs 2032
1.3.2 Infant patients
1.3.3 Child patients
1.3.4 Youth patients
1.3.5 Elderly patients
1.4 Global Gastric Mucosal Protective Drugs Market Size Estimates and Forecasts
1.4.1 Global Gastric Mucosal Protective Drugs Revenue 2021–2032
1.4.2 Global Gastric Mucosal Protective Drugs Sales 2021–2032
1.4.3 Global Gastric Mucosal Protective Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Gastric Mucosal Protective Drugs Market Competition by Manufacturers
2.1 Global Gastric Mucosal Protective Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Gastric Mucosal Protective Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Gastric Mucosal Protective Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Gastric Mucosal Protective Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Gastric Mucosal Protective Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Gastric Mucosal Protective Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Gastric Mucosal Protective Drugs, Date of Entry into the Industry
2.8 Global Gastric Mucosal Protective Drugs Market Competitive Situation and Trends
2.8.1 Global Gastric Mucosal Protective Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Gastric Mucosal Protective Drugs Players Market Share by Revenue
2.8.3 Global Gastric Mucosal Protective Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Gastric Mucosal Protective Drugs Market Scenario by Region
3.1 Global Gastric Mucosal Protective Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Gastric Mucosal Protective Drugs Sales by Region: 2021–2032
3.2.1 Global Gastric Mucosal Protective Drugs Sales by Region: 2021–2026
3.2.2 Global Gastric Mucosal Protective Drugs Sales by Region: 2027–2032
3.3 Global Gastric Mucosal Protective Drugs Revenue by Region: 2021–2032
3.3.1 Global Gastric Mucosal Protective Drugs Revenue by Region: 2021–2026
3.3.2 Global Gastric Mucosal Protective Drugs Revenue by Region: 2027–2032
3.4 North America Gastric Mucosal Protective Drugs Market Facts & Figures by Country
3.4.1 North America Gastric Mucosal Protective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Gastric Mucosal Protective Drugs Sales by Country (2021–2032)
3.4.3 North America Gastric Mucosal Protective Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Gastric Mucosal Protective Drugs Market Facts & Figures by Country
3.5.1 Europe Gastric Mucosal Protective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Gastric Mucosal Protective Drugs Sales by Country (2021–2032)
3.5.3 Europe Gastric Mucosal Protective Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gastric Mucosal Protective Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Gastric Mucosal Protective Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Gastric Mucosal Protective Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Gastric Mucosal Protective Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Gastric Mucosal Protective Drugs Market Facts & Figures by Country
3.7.1 Latin America Gastric Mucosal Protective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Gastric Mucosal Protective Drugs Sales by Country (2021–2032)
3.7.3 Latin America Gastric Mucosal Protective Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Gastric Mucosal Protective Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Gastric Mucosal Protective Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Gastric Mucosal Protective Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021–2032)
4.1.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021–2026)
4.1.2 Global Gastric Mucosal Protective Drugs Sales by Type (2027–2032)
4.1.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021–2032)
4.2 Global Gastric Mucosal Protective Drugs Revenue by Type (2021–2032)
4.2.1 Global Gastric Mucosal Protective Drugs Revenue by Type (2021–2026)
4.2.2 Global Gastric Mucosal Protective Drugs Revenue by Type (2027–2032)
4.2.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Gastric Mucosal Protective Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021–2032)
5.1.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021–2026)
5.1.2 Global Gastric Mucosal Protective Drugs Sales by Application (2027–2032)
5.1.3 Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021–2032)
5.2 Global Gastric Mucosal Protective Drugs Revenue by Application (2021–2032)
5.2.1 Global Gastric Mucosal Protective Drugs Revenue by Application (2021–2026)
5.2.2 Global Gastric Mucosal Protective Drugs Revenue by Application (2027–2032)
5.2.3 Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Gastric Mucosal Protective Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Misoprostol (Cytotec)
6.1.1 Misoprostol (Cytotec) Company Information
6.1.2 Misoprostol (Cytotec) Description and Business Overview
6.1.3 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product Portfolio
6.1.5 Misoprostol (Cytotec) Recent Developments/Updates
6.2 Sucralfate (Carafate)
6.2.1 Sucralfate (Carafate) Company Information
6.2.2 Sucralfate (Carafate) Description and Business Overview
6.2.3 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product Portfolio
6.2.5 Sucralfate (Carafate) Recent Developments/Updates
6.3 Bismuth Subsalicylate (Pepto-Bismol)
6.3.1 Bismuth Subsalicylate (Pepto-Bismol) Company Information
6.3.2 Bismuth Subsalicylate (Pepto-Bismol) Description and Business Overview
6.3.3 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product Portfolio
6.3.5 Bismuth Subsalicylate (Pepto-Bismol) Recent Developments/Updates
6.4 Abbott
6.4.1 Abbott Company Information
6.4.2 Abbott Description and Business Overview
6.4.3 Abbott Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Abbott Gastric Mucosal Protective Drugs Product Portfolio
6.4.5 Abbott Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Company Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 AstraZeneca Gastric Mucosal Protective Drugs Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Cadila Healthcare
6.6.1 Cadila Healthcare Company Information
6.6.2 Cadila Healthcare Description and Business Overview
6.6.3 Cadila Healthcare Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Cadila Healthcare Gastric Mucosal Protective Drugs Product Portfolio
6.6.5 Cadila Healthcare Recent Developments/Updates
6.7 Daewoong Pharmaceutical
6.7.1 Daewoong Pharmaceutical Company Information
6.7.2 Daewoong Pharmaceutical Description and Business Overview
6.7.3 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
6.7.5 Daewoong Pharmaceutical Recent Developments/Updates
6.8 Eisai
6.8.1 Eisai Company Information
6.8.2 Eisai Description and Business Overview
6.8.3 Eisai Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Eisai Gastric Mucosal Protective Drugs Product Portfolio
6.8.5 Eisai Recent Developments/Updates
6.9 Pharmaking
6.9.1 Pharmaking Company Information
6.9.2 Pharmaking Description and Business Overview
6.9.3 Pharmaking Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Pharmaking Gastric Mucosal Protective Drugs Product Portfolio
6.9.5 Pharmaking Recent Developments/Updates
6.10 Taiho Pharmaceutical
6.10.1 Taiho Pharmaceutical Company Information
6.10.2 Taiho Pharmaceutical Description and Business Overview
6.10.3 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
6.10.5 Taiho Pharmaceutical Recent Developments/Updates
6.11 Takeda Pharmaceutical
6.11.1 Takeda Pharmaceutical Company Information
6.11.2 Takeda Pharmaceutical Description and Business Overview
6.11.3 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
6.11.5 Takeda Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gastric Mucosal Protective Drugs Industry Chain Analysis
7.2 Gastric Mucosal Protective Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gastric Mucosal Protective Drugs Production Mode & Process Analysis
7.4 Gastric Mucosal Protective Drugs Sales and Marketing
7.4.1 Gastric Mucosal Protective Drugs Sales Channels
7.4.2 Gastric Mucosal Protective Drugs Distributors
7.5 Gastric Mucosal Protective Drugs Customer Analysis
8 Gastric Mucosal Protective Drugs Market Dynamics
8.1 Gastric Mucosal Protective Drugs Industry Trends
8.2 Gastric Mucosal Protective Drugs Market Drivers
8.3 Gastric Mucosal Protective Drugs Market Challenges
8.4 Gastric Mucosal Protective Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Gastric Mucosal Protective Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Gastric Mucosal Protective Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Gastric Mucosal Protective Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Gastric Mucosal Protective Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Gastric Mucosal Protective Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Gastric Mucosal Protective Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Gastric Mucosal Protective Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Gastric Mucosal Protective Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Gastric Mucosal Protective Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Gastric Mucosal Protective Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Gastric Mucosal Protective Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Gastric Mucosal Protective Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gastric Mucosal Protective Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Gastric Mucosal Protective Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gastric Mucosal Protective Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Gastric Mucosal Protective Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Gastric Mucosal Protective Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Gastric Mucosal Protective Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Gastric Mucosal Protective Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Gastric Mucosal Protective Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Gastric Mucosal Protective Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Gastric Mucosal Protective Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Gastric Mucosal Protective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Gastric Mucosal Protective Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Gastric Mucosal Protective Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Gastric Mucosal Protective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Gastric Mucosal Protective Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Gastric Mucosal Protective Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Gastric Mucosal Protective Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Gastric Mucosal Protective Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Gastric Mucosal Protective Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Gastric Mucosal Protective Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Gastric Mucosal Protective Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Gastric Mucosal Protective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Gastric Mucosal Protective Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Gastric Mucosal Protective Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Gastric Mucosal Protective Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Gastric Mucosal Protective Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Gastric Mucosal Protective Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Gastric Mucosal Protective Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Gastric Mucosal Protective Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Gastric Mucosal Protective Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Gastric Mucosal Protective Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Gastric Mucosal Protective Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Gastric Mucosal Protective Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Gastric Mucosal Protective Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Misoprostol (Cytotec) Company Information
Table 71. Misoprostol (Cytotec) Description and Business Overview
Table 72. Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product
Table 74. Misoprostol (Cytotec) Recent Developments/Updates
Table 75. Sucralfate (Carafate) Company Information
Table 76. Sucralfate (Carafate) Description and Business Overview
Table 77. Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product
Table 79. Sucralfate (Carafate) Recent Developments/Updates
Table 80. Bismuth Subsalicylate (Pepto-Bismol) Company Information
Table 81. Bismuth Subsalicylate (Pepto-Bismol) Description and Business Overview
Table 82. Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product
Table 84. Bismuth Subsalicylate (Pepto-Bismol) Recent Developments/Updates
Table 85. Abbott Company Information
Table 86. Abbott Description and Business Overview
Table 87. Abbott Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Abbott Gastric Mucosal Protective Drugs Product
Table 89. Abbott Recent Developments/Updates
Table 90. AstraZeneca Company Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. AstraZeneca Gastric Mucosal Protective Drugs Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Cadila Healthcare Company Information
Table 96. Cadila Healthcare Description and Business Overview
Table 97. Cadila Healthcare Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Cadila Healthcare Gastric Mucosal Protective Drugs Product
Table 99. Cadila Healthcare Recent Developments/Updates
Table 100. Daewoong Pharmaceutical Company Information
Table 101. Daewoong Pharmaceutical Description and Business Overview
Table 102. Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product
Table 104. Daewoong Pharmaceutical Recent Developments/Updates
Table 105. Eisai Company Information
Table 106. Eisai Description and Business Overview
Table 107. Eisai Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Eisai Gastric Mucosal Protective Drugs Product
Table 109. Eisai Recent Developments/Updates
Table 110. Pharmaking Company Information
Table 111. Pharmaking Description and Business Overview
Table 112. Pharmaking Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Pharmaking Gastric Mucosal Protective Drugs Product
Table 114. Pharmaking Recent Developments/Updates
Table 115. Taiho Pharmaceutical Company Information
Table 116. Taiho Pharmaceutical Description and Business Overview
Table 117. Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product
Table 119. Taiho Pharmaceutical Recent Developments/Updates
Table 120. Takeda Pharmaceutical Company Information
Table 121. Takeda Pharmaceutical Description and Business Overview
Table 122. Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product
Table 124. Takeda Pharmaceutical Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Gastric Mucosal Protective Drugs Distributors List
Table 128. Gastric Mucosal Protective Drugs Customers List
Table 129. Gastric Mucosal Protective Drugs Market Trends
Table 130. Gastric Mucosal Protective Drugs Market Drivers
Table 131. Gastric Mucosal Protective Drugs Market Challenges
Table 132. Gastric Mucosal Protective Drugs Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Gastric Mucosal Protective Drugs
Figure 2. Global Gastric Mucosal Protective Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Gastric Mucosal Protective Drugs Market Share by Type: 2025 & 2032
Figure 4. Oral Medicines Product Picture
Figure 5. Injectable Medicines Product Picture
Figure 6. Global Gastric Mucosal Protective Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Gastric Mucosal Protective Drugs Market Share by Application: 2025 & 2032
Figure 8. Infant patients
Figure 9. Child patients
Figure 10. Youth patients
Figure 11. Elderly patients
Figure 12. Global Gastric Mucosal Protective Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Gastric Mucosal Protective Drugs Market Size (US$ Million), 2021–2032
Figure 14. Global Gastric Mucosal Protective Drugs Sales (K Units), 2021–2032
Figure 15. Global Gastric Mucosal Protective Drugs Average Price (US$/Unit), 2021–2032
Figure 16. Gastric Mucosal Protective Drugs Report Years Considered
Figure 17. Gastric Mucosal Protective Drugs Sales Share by Manufacturers in 2025
Figure 18. Global Gastric Mucosal Protective Drugs Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Gastric Mucosal Protective Drugs Players: Market Share by Revenue in Gastric Mucosal Protective Drugs in 2025
Figure 20. Gastric Mucosal Protective Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Gastric Mucosal Protective Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Gastric Mucosal Protective Drugs Sales Market Share by Country (2021–2032)
Figure 23. North America Gastric Mucosal Protective Drugs Revenue Market Share by Country (2021–2032)
Figure 24. United States Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Gastric Mucosal Protective Drugs Sales Market Share by Country (2021–2032)
Figure 27. Europe Gastric Mucosal Protective Drugs Revenue Market Share by Country (2021–2032)
Figure 28. Germany Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Gastric Mucosal Protective Drugs Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Gastric Mucosal Protective Drugs Revenue Market Share by Region (2021–2032)
Figure 35. China Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Gastric Mucosal Protective Drugs Sales Market Share by Country (2021–2032)
Figure 43. Latin America Gastric Mucosal Protective Drugs Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Gastric Mucosal Protective Drugs Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Gastric Mucosal Protective Drugs Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Gastric Mucosal Protective Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Gastric Mucosal Protective Drugs by Type (2021–2032)
Figure 54. Global Revenue Market Share of Gastric Mucosal Protective Drugs by Type (2021–2032)
Figure 55. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of Gastric Mucosal Protective Drugs by Application (2021–2032)
Figure 57. Global Revenue Market Share of Gastric Mucosal Protective Drugs by Application (2021–2032)
Figure 58. Global Gastric Mucosal Protective Drugs Price (US$/Unit) by Application (2021–2032)
Figure 59. Gastric Mucosal Protective Drugs Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
